Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Clinical Trials01:16

Clinical Trials

11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.6K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective Communication at a High-Containment Facility: How Information Consistency and Sufficiency Affect Knowledge, Risk Perceptions, and Community Preparedness for Potential Biological Hazards.

Applied biosafety : journal of the American Biological Safety AssociationĀ·2026
Same author

Sensitivity of HiFi long-read genome sequencing for difficult-to-detect pathogenic variants when applied to real-world clinical laboratory samples.

American journal of human geneticsĀ·2026
Same author

Development of a machine learning-based survival prediction model for ALS inclusive of the advanced-stage population.

Amyotrophic lateral sclerosis & frontotemporal degenerationĀ·2026
Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

NatureĀ·2026
Same author

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

JAMA neurologyĀ·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degenerationĀ·2026

Related Experiment Video

Updated: Apr 18, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.9K

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Neta Zach1, David L Ennist, Albert A Taylor

  • 1Prize4Life, Tel aviv, Israel, nzach@Prize4Life.org.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 24, 2015
PubMed
Summary

The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) platform provides a large dataset for amyotrophic lateral sclerosis (ALS) research. This resource enables better understanding of ALS progression and improves clinical trial design.

More Related Videos

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

36.3K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.9K

Related Experiment Videos

Last Updated: Apr 18, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.9K
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

36.3K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.9K

Area of Science:

  • Neuroscience
  • Clinical Research
  • Data Science

Background:

  • Characterizing patient populations is crucial for advancing research and clinical care in rare diseases like amyotrophic lateral sclerosis (ALS).
  • The development of large, accessible patient datasets is essential for effective clinical trial design and execution.
  • The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) platform was created to address the need for a substantial ALS patient cohort.

Purpose of the Study:

  • To provide an overview of research enabled by the PRO-ACT database.
  • To highlight the value of large datasets in understanding ALS natural history and prognostic factors.
  • To showcase the development of tools for improved clinical trial recruitment and monitoring.

Main Methods:

  • The PRO-ACT database aggregates over 8600 patient records from 17 completed ALS clinical trials.
  • Data access is provided in an open-access mode to researchers globally.
  • The platform facilitates various research analyses, including prediction modeling and patient stratification.

Main Results:

  • Research using PRO-ACT data has led to predictions of ALS progression and survival.
  • Novel predictors of disease progression and survival have been discovered.
  • New patient stratification based on disease progression profiles has been identified.
  • Tools for enhanced clinical trial recruitment and monitoring have been developed.

Conclusions:

  • Large, open-access datasets like PRO-ACT are invaluable for advancing the understanding of ALS.
  • The PRO-ACT platform has facilitated significant research into ALS natural history, prognosis, and patient stratification.
  • Continued analysis of the PRO-ACT database promises further insights into ALS, a disease that has long challenged scientific understanding.